| Affiliation: | 1. Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, USA;2. Oncology Institute and Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel;3. Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, USA;4. Department of Gynaecological Oncology, City Clinical Oncology Dispensary, Saint Petersburg, Russia;5. Department of Urogynaecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G Pascale”, IRCCS, Naples, Italy;6. Department of Obstetrics and Gynaecology and Gynaecologic Oncology, University Hospital Leuven, Leuven, Belgium;7. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy;8. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands;9. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA;10. Hôpital Notre-Dame - Pavillon L-C Simard, Centre Hospitalier de L’Université de Montréal (CHUM), Montreal, Canada;11. Gynecology and Obstetrics, Charité-Medical University of Berlin, Berlin, Germany;12. Department of Surgical Sciences, University of Milano-Bicocca and European Institute of Oncology, Milano, Italy;13. Medical Oncology, Clinica Universidad de Navarra; formerly of MD Anderson International España, Madrid;14. Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;15. Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands;16. Clinic of Obstetrics and Gynecology, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania;17. Companion Diagnostics, Merck & Co., Inc, Kenilworth, USA;18. BARDS, MSD China, Beijing, China;19. Clinical Development, Merck & Co., Inc., Kenilworth, USA;20. UCL Cancer Institute and UCL Hospitals, Department of Oncology, University College London, London, UK |
